Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Symbicort TBH- Turbuhaler · 1 trial · 1 indication
Time to severe exacerbation among patients
| Arm | Type | Description |
|---|---|---|
| Symbicort | EXPERIMENTAL | Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed) |
| Conventional BP | EXPERIMENTAL | Conventional Best Practice for Treatment of Asthma |
| Name | Type | Description |
|---|---|---|
| Symbicort TBH - Turbuhaler | DRUG | Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed) |
| beta-II-agonist, inhale steroid | DRUG | Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage |
Inclusion Criteria: * Signed informed consent form. If the patient cannot read and write, verbal consent from the patient is required. * Ability to read and write in Turkish * Female or male outpatients aged 18 years * Minimum of 3 months history of asthma, diagnosed according to the American Thora...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Symbicort TBH - Turbuhaler is an investigational small molecule therapy being developed by AstraZeneca PLC for the treatment of asthma. It is a Phase 3 candidate in the respiratory therapeutic area. The product is also written as Symbicort TBH- Turbuhaler, and both names refer to the same asset.
Symbicort TBH - Turbuhaler is being studied for the treatment of persistent asthma in adults. The single Phase 3 trial enrolled patients aged 18 years and older with persistent asthma, comparing single inhaler therapy against conventional best practice. It is not described as approved and remains in clinical development.
Symbicort TBH - Turbuhaler is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor behind the clinical program for this asthma candidate.
Symbicort TBH - Turbuhaler is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program is investigational and has not been described as approved for any indication.
Symbicort TBH - Turbuhaler has been evaluated in one completed Phase 3 trial, NCT00628758, titled A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma. The trial enrolled 430 adults in Turkey, was randomized and controlled, and included both male and female participants.
Yes, Symbicort TBH - Turbuhaler and Symbicort TBH- Turbuhaler are the same asset, with only minor punctuation differences in the name. Both refer to the AstraZeneca PLC Phase 3 asthma candidate evaluated in trial NCT00628758.